- FDA has approved the novel EEG device, Minder, for marketing among patients with drug-resistant epilepsy.
- Minder enables continuous EEG monitoring for extended periods, potentially providing support for epilepsy management and clinical decision-making.
- Approval was supported by the UMPIRE trial, demonstrating the device's capacity to offer long-term, ambulatory EEG data of sufficient quality to inform clinical decisions.
Source: Epiminder
